Abstract
The therapeutic efficacy and safety of oral itraconazole (200 mg/day for 7 days) was assessed in an open trial in 50 patients with pityriasis versicolor. At the end of the 1-week therapy complete remission and marked improvement were observed in 44% and 48% of the treated patients, respectively; 8% of the patients who showed no response were treated for 1 more week and also revealed a complete remission by the end of the 3-week follow-up (5050). Headache and/or nausea occurred in 6% of the patients, whereas, the haematological and biochemical investigations revealed no abnormalities. The results of the present study clearly indicate that oral itraconazole is a highly efficacious and safe treatment for pityriasis versicolor.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
